1. Pópulo H, Lopes JM, Sobrinho-Simões M, Soares P

RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. Journal of the National Cancer Institute 107: 1, 2015.  [Letter] 

 doi: 10.1093/jnci/djv049 PMID: 25755155.

 

2. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P

Frequency of TERT promoter mutations in human cancers. Nature communications 4: 2185, 2013.  [Article] 

 doi: 10.1038/ncomms3185 PMID: 23887589.

 

3. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P

TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. The Journal of investigative dermatology 134: 2251-7, 2014.  [Article] 

 doi: 10.1038/jid.2014.163 PMID: 24691053.

 

4. Faustino A, Couto JP, Pópulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M, Soares P

mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. The Journal of clinical endocrinology and metabolism 97: E1139-49, 2012.  [Article] 

 doi: 10.1210/jc.2011-2748 PMID: 22549934.

 

5. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM

mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment cell & melanoma research 24: 254-7, 2011.  [Letter] 

 doi: 10.1111/j.1755-148X.2010.00796.x PMID: 21029395.

 

6. Pópulo H, Caldas R, Lopes JM, Pardal J, Máximo V, Soares P

Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert opinion on therapeutic targets 19: 733-45, 2015.  [Article] 

 doi: 10.1517/14728222.2015.1045416 PMID: 25976231.

 

7. Pópulo H, Soares P, Lopes JM

Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert opinion on therapeutic targets 16: 689-705, 2012.  [Review] 

 doi: 10.1517/14728222.2012.691472 PMID: 22620498.

 

8. Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S

Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. PloS one 10: e0122308, 2015.  [Article] 

 doi: 10.1371/journal.pone.0122308 PMID: 25822260.

 

9. Pópulo H, Vinagre J, Lopes JM, Soares P

Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. The British journal of ophthalmology 95: 715-9, 2011.  [Article] 

 doi: 10.1136/bjo.2009.174417 PMID: 20805136.

 

10. Pópulo H, Batista R, Sampaio C, Pardal J, Lopes JM, Soares P

SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PloS one 12: e0180392, 2017.  [Article] 

 doi: 10.1371/journal.pone.0180392 PMID: 28662141.

 

11. Mesquita P, Freire AF, Lopes N, Gomes R, Azevedo D, Barros R, Pereira B, Cavadas B, Pópulo H, Boaventura P, David L, Pereira L, Almeida R

Expression and Clinical Relevance of SOX9 in Gastric Cancer. Disease markers 2019: 8267021, 2019.  [Article] 

 doi: 10.1155/2019/8267021 PMID: 31275454.

 

12. Vinagre J, Pópulo H, Azevedo F, Soares P, Lopes JM

 Expression of pS6 Ser235/236 effector of mTOR pathway may be a prognostic parameter in patients with cutaneous melanomas Virchows Archiv  1, 2012.  [Meeting Abstract] 

.

 

13. Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Máximo V, Sobrinho-Simões M, Soares P

Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv : an international journal of pathology 465: 119-33, 2014.  [Review] 

 doi: 10.1007/s00428-014-1608-4 PMID: 25048572.

 

14. Pópulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, Miranda-Alves L, Cai RZ, Zhang XY, Schally AV, Sobrinho-Simões M, Soares P

Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones & cancer 8: 314-324, 2017.  [Article] 

 doi: 10.1007/s12672-017-0307-4 PMID: 28924876.

 

15. Pópulo H, Lopes JM, Soares P

The mTOR Signalling Pathway in Human Cancer. International journal of molecular sciences 13: 1886-918, 2012.  [Review] 

 doi: 10.3390/ijms13021886 PMID: 22408430.

 

16. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma research 20: 107-17, 2010.  [Article] 

 doi: 10.1097/CMR.0b013e32832ccd09 PMID: 20173664.

 

17. Vala H, Pópulo H, Mesquita JR, Esteves F, Santos C, Soares P, Lopes JM

Melanocytic tumour in a black sheep never exposed to ultraviolet radiation. Journal of comparative pathology 146: 160-4, 2012.  [Article] 

 doi: 10.1016/j.jcpa.2011.04.001 PMID: 21612790.

 

18. Domingues B, Lopes JM, Soares P, Pópulo H

Melanoma treatment in review. ImmunoTargets and therapy 7: 35-49, 2018.  [Review] 

 doi: 10.2147/ITT.S134842 PMID: 29922629.

 

19. Pópulo H, Tavares S, Faustino A, Nunes JB, Lopes JM, Soares P

GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ 1: e104, 2013.  [Article] 

 doi: 10.7717/peerj.104 PMID: 23904987.